Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced that new data on ...

The European medicines regulator said that a higher rate of death and disease complications in recent trials meant the ...

Azlind Davis' immune system was mistakenly attacking her red blood cells, causing anemia. A blood drive is scheduled for Oct.

The EPIC study will evaluate treatment with IMAAVY™ versus efgartigimod in adults with gMG and will include a treatment-switch arm The Company also announced new data from the pivotal Vibrance-MG ...

Phototherapy is a common treatment for babies with hemolytic disease of the fetus and newborn (HDFN) and severe jaundice.

The drug, dubbed ianalumab, both depletes B cells and deactivates those remaining, Thomas Grader-Beck, MD, of Johns Hopkins ...

Vertex Pharmaceuticals Incorporated remains a leader in CF treatments, fueling robust cash flow and pipeline expansions.

Copper is an essential trace mineral vital for energy production, connective tissue integrity, and brain health, helping to ...

Debt Management: Agios Pharmaceuticals's debt-to-equity ratio is below the industry average. With a ratio of 0.04, the company relies less on debt financing, maintaining a healthier balance between ...

Detailed price information for 60 Degrees Pharmaceuticals Inc (SXTP-Q) from The Globe and Mail including charting and trades.

Omeros Corporation maintained with Strong Buy rating after securing a $2.1 billion partnership with Novo Nordisk for zaltenibart. Click for my OMER update.

Takeda (TSE:4502/NYSE:TAK) today announced that the recently FDA-approved HyHub and HyHub Duo devices are now available in the U.S. for patients 17 years of age and older, as prescribed, who are ...